title: Dose-dependent EEG effects of zolpidem provide evidence for GABA(A) receptor subtype selectivity in vivo.
abstract: Zolpidem is a nonbenzodiazepine GABA(A) receptor modulator that binds in vitro with high affinity to GABA(A) receptors expressing alpha(1) subunits but with relatively low affinity to receptors expressing alpha(2), alpha(3), and alpha(5) subunits. In the present study, it was investigated whether this subtype selectivity could be detected and quantified in vivo. Three doses (1.25, 5, and 25 mg) of zolpidem were administered to rats in an intravenous infusion over 5 min. The time course of the plasma concentrations was determined in conjunction with the change in the beta-frequency range of the EEG as pharmacodynamic endpoint. The concentration-effect relationship of the three doses showed a dose-dependent maximum effect and a dose-dependent potency. The data were analyzed for one- or two-site binding using two pharmacodynamic models based on 1) the descriptive model and 2) a novel mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) model for GABA(A) receptor modulators that aims to separates drug- and system-specific properties, thereby allowing the estimation of in vivo affinity and efficacy. The application of two-site models significantly improved the fits compared with one-site models. Furthermore, in contrast to the descriptive model, the mechanism-based PK/PD model yielded dose-independent estimates for affinity (97 +/- 40 and 33,100 +/- 14,800 ng x ml(-1)). In conclusion, the mechanism-based PK/PD model is able to describe and explain the observed dose-dependent EEG effects of zolpidem and suggests the subtype selectivity of zolpidem in vivo.
authors.affiliation: Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands. sandra.visser@astrazeneca.com
authors.forename: S A G
authors.initials: SA
authors.lastname: Visser
authors.forename: F L C
authors.initials: FL
authors.lastname: Wolters
authors.forename: P H
authors.initials: PH
authors.lastname: van der Graaf
authors.forename: L A
authors.initials: LA
authors.lastname: Peletier
authors.forename: M
authors.initials: M
authors.lastname: Danhof
mesh_terms: D000818:Animals; D001665:Binding Sites; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography / Q000187:drug effects*; D018755:GABA Agonists / Q000493:pharmacokinetics* / Q000494:pharmacology; D008297:Male; D023421:Models, Animal; D011725:Pyridines / Q000493:pharmacokinetics* / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011963:Receptors, GABA-A / Q000145:classification / Q000378:metabolism*; D000077334:Zolpidem
chemical_list: D018755:GABA Agonists; D011725:Pyridines; D011963:Receptors, GABA-A; D000077334:Zolpidem